NEW YORK (AP) _ Progenics Pharmaceuticals Inc. (PGNX) on Thursday reported a loss of $24.4 million in its third quarter.
The New York-based company said it had a loss of 30 cents per share. Losses, adjusted for one-time gains and costs, were 9 cents per share.
The biopharmaceutical company posted revenue of $5.3 million in the period.
Progenics shares have fallen nearly 6 percent since the beginning of the year. The stock has increased roughly 1 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PGNX at https://www.zacks.com/ap/PGNX